# Breathe Biomedical — Healthcare Investment Intelligence

> diagnostics. MedFuel Intel profile as of 2026-06-12.

Breathe BioMedical is developing a breath analytics platform technology to detect early-stage breast cancer in women with dense breast tissue as an adjunct to mammography, using breath samples analyzed via proprietary infrared spectrometer and machine learning algorithms. The company launched a multi-center clinical trial in February 2025 at George Washington University Breast Center, with research showing 88.2% accuracy in identifying breath signatures of early-stage breast cancer.[1][2][3]

## Key facts (as of 2026-06-12)
- Sector: diagnostics
- Website: https://breathebiomedical.com/

## MedFuel assessment
- Intelligence score: 15/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/breathe-biomedical-2. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.